Abstract

Herceptin is a successful clinical agent, both in monotherapy and in combination therapy, in the fight against breast cancer. However, not all patients will benefit from this therapy. In conjunction with Dr. Martin Brechbiel we have developed a 111In labeled Herceptin Scan that enables the visualization of the distribution of HER2/neu receptors in the body and within tumors. This agent, which has been thoroughly evaluated in mice, has received preliminary approval for introduction into man in a Phase 0 study. In collaboration with the DDG we are manufacturing this agent for use in human trials in the Clinical Center to assess the biodistribution of Herceptin and monitor response. This study will serve as a basis for estimating dosimetry for future trials using radioimmunotherapy with alpha-emitters chelated to Herceptin, particularly in metastatic disease localized to the peritoneum.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Basic Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01BC010656-02
Application #
7338755
Study Section
(MIP)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2006
Total Cost
Indirect Cost

  Institution

Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Ogawa, Mikako; Kosaka, Nobuyuki; Longmire, Michelle R et al. (2009) Fluorophore-Quencher Based Activatable Targeted Optical Probes for Detecting in Vivo Cancer Metastases. Mol Pharm :
Ogawa, Mikako; Kosaka, Nobuyuki; Choyke, Peter L et al. (2009) In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 69:1268-72
Kamiya, Mako; Kobayashi, Hisataka; Hama, Yukihiro et al. (2007) An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc 129:3918-29
Koyama, Yoshinori; Barrett, Tristan; Hama, Yukihiro et al. (2007) In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. Neoplasia 9:1021-9
Hama, Yukihiro; Urano, Yasuteru; Koyama, Yoshinori et al. (2007) Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. Cancer Res 67:3809-17
Xu, Heng; Regino, Celeste A S; Koyama, Yoshinori et al. (2007) Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging. Bioconjug Chem 18:1474-82
Barrett, Tristan; Koyama, Yoshinori; Hama, Yukihiro et al. (2007) In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res 13:6639-48
Koyama, Yoshinori; Hama, Yukihiro; Urano, Yasuteru et al. (2007) Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu. Clin Cancer Res 13:2936-45
Hama, Yukihiro; Urano, Yasuteru; Koyama, Yoshinori et al. (2007) A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate. Cancer Res 67:2791-9
Xu, Heng; Baidoo, Kwamena; Gunn, Andrew J et al. (2007) Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 50:4759-65

Showing the most recent 10 out of 13 publications